The role of topotecan in treating small cell lung cancer: second-line treatment

被引:18
作者
von Pawel, J [1 ]
机构
[1] Asklepios Fachklin, Munich, Germany
关键词
second-line treatment; single-agent chemotherapy; small-cell lung cancer; topotecan;
D O I
10.1016/S0169-5002(03)90519-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Small-cell lung cancer (SCLC) is highly chemosensitive but up to 70% of patients with limited disease and more than 90% of patients with extensive disease will relapse after first-line treatment. There are several standard chemotherapy regimens used for second-line treatment yet the prognosis for patients requiring this treatment remains poor. The topoisomerase-I inhibitor, topotecan, has achieved response rates of up to 22% in previously treated patients with SCLC and survival almost double that achieved with other single agents. Compared with cyclophosphanide/doxorubicin/vincristine (CAV), single-agent topotecan achieved a higher response rate, longer survival and statistically significant improvements in dyspnea, hoarseness, fatigue, anorexia and interference with daily activities. Brain metastases are common in SCLC. Topotecan crosses the blood-brain barrier and shows promise for the management of brain metastases. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:S3 / S8
页数:6
相关论文
共 31 条
[1]   Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease [J].
Ardizzoni, A ;
Hansen, H ;
Dombernowsky, P ;
Gamucci, T ;
Kaplan, S ;
Postmus, P ;
Giaccone, G ;
Schaefer, B ;
Wanders, J ;
Verweij, J .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) :2090-2096
[2]  
ARDIZZONI A, 1996, ANN ONCOL, V7, pA509
[3]  
Baker SD, 1996, CANCER CHEMOTH PHARM, V37, P195
[4]   ACTIVITY OF TOPOTECAN, A NEW TOPOISOMERASE-I INHIBITOR, AGAINST HUMAN TUMOR COLONY-FORMING-UNITS INVITRO [J].
BURRIS, HA ;
HANAUSKE, AR ;
JOHNSON, RK ;
MARSHALL, MH ;
KUHN, JG ;
HILSENBECK, SG ;
VONHOFF, DD .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (23) :1816-1820
[5]  
Cesano A, 1999, INT J ONCOL, V15, P1233
[6]  
DEPIERRE A, 1997, LUNG CANCER S, V18, pA126
[7]  
Eckardt J, 1996, ANN ONCOL, V107, pA513
[8]  
ECKARDT JR, 2003, P AN M AM SOC CLIN, V22, P2488
[9]   RANDOMIZED TRIAL OF CYCLOPHOSPHAMIDE, DOXORUBICIN, AND VINCRISTINE VERSUS CISPLATIN AND ETOPOSIDE VERSUS ALTERNATION OF THESE REGIMENS IN SMALL-CELL LUNG-CANCER [J].
FUKUOKA, M ;
FURUSE, K ;
SAIJO, N ;
NISHIWAKI, Y ;
IKEGAMI, H ;
TAMURA, T ;
SHIMOYAMA, M ;
SUEMASU, K .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (12) :855-861
[10]  
GERRITS CJH, 1996, ANN ONCOL, V7, pO597